Jenny Goldstein

From the Patient’s Bedside to the World

Some of the most important questions in medicine do not begin in a laboratory. They begin with a patient.

A physician sees someone whose treatment is not working as expected. A surgeon encounters a problem for which the existing tools are not quite good enough. A patient asks a question that medicine cannot yet answer.

What happens next?

Ideally, that question travels. From the hospital room to a scientist. From the scientist to an engineer. And ultimately, back to the patient in the form of something better: a more precise diagnosis, a new therapy, or a treatment that did not exist before.

That journey is at the heart of an exciting new collaboration between the Technion and Rambam Health Care Campus in Haifa: the Andrea and Lawrence Wolfe Center for Translational Medicine and Engineering.

For me, there is also a personal dimension to this story. I have the privilege of knowing Andi and Larry Wolfe, and I know how deeply their commitment to the Technion and Israel runs. Their support reflects a relationship built over many years and a genuine belief in what Israeli science and innovation can contribute to the world.

And for those of us who care about Israeli innovation and Jewish philanthropy, I think it offers an important lesson about what impact really looks like.

In previous posts, I have written about the importance of translating Israel’s extraordinary innovation into something larger than a source of pride. For those of us engaged in Jewish philanthropy, our challenge is to show how discoveries emerging from Israel can improve someone’s life anywhere on Earth.

The new Center gives that idea a physical home.

When Medicine Meets Engineering

Made possible by the generosity of Andi and Larry Wolfe, the Center will bring physicians, scientists, and engineers together in the Helmsley Health Discovery Tower at Rambam.

Its research will span artificial intelligence and medicine, biochips, drug delivery and molecular therapies, medical devices, tissue engineering and regenerative medicine, and healthcare systems operations.

But what interests me most is not any one field. It is what can happen between them.

Medical problems rarely respect the boundaries of academic disciplines. A physician may understand exactly what a patient needs but not know how to engineer the solution. A scientist may uncover an important biological mechanism but not know how it could become a treatment. An engineer may develop an extraordinary technology without having direct access to the clinical problem where it could matter most.

Bring those people together, however, and something changes.

Technion President Prof. Uri Sivan described the partnership as providing the entire value chain, “from the patient’s bedside to the research and development laboratories and back to the patient’s bedside.”

I love that image because it reminds us what the real destination of medical research should be.

Not the laboratory. Not the research paper. Not even the patent.

The patient.

Breakthroughs Happen Between Worlds

One example shared at the Center’s launch was Kurt Semm, the physician and ingenious toolmaker whose work helped pioneer modern laparoscopy. Today, minimally invasive surgery is so familiar that it is easy to forget what a radical change it represented. That transformation did not come from medicine alone. It required someone who could see a clinical challenge and think like a physician and a technologist at the same time.

As Rambam Director General Dr. Michal Mekel put it, “Breakthroughs emerge when different worlds meet, and in our case, when medicine meets engineering.”

We already see that happening between the Technion and Rambam. A recent joint research competition focused on implementing artificial intelligence in the hospital of the future brought together expertise from architecture and town planning, data and decision sciences, Rambam’s Ambulatory Services Division, and hospital administration.

At first glance, those fields might seem to have little in common. But improving healthcare requires us to look at the whole picture. That is what interdisciplinary collaboration makes possible.

From Israeli Innovation to Human Possibility 

We often talk about Israeli innovation in terms of achievement. We celebrate extraordinary scientists. We point to startups, patents, discoveries, and technologies. And we should.

But admiration is only the beginning. The more important question is: What becomes possible because of that innovation?

I learned this lesson repeatedly during the years I spent working in international development and healthcare. Where someone happens to be born can still profoundly affect the healthcare they receive and the technologies available to their physicians.

That is why I am so drawn to work that begins with real human needs and asks different kinds of thinkers to solve them together.

Prof. Lior Gepstein, who leads Rambam’s Research Division and is also a Technion faculty member, captured this beautifully. New solutions, he explained, require medical teams who understand patients’ needs firsthand, scientists who understand the mechanisms of life, and engineers who know how to transform an idea into something practical. 

The world is full of brilliant ideas. The challenge is turning brilliance into something a person can actually use.

Philanthropy as a Bridge

That is where philanthropy enters this story.

Knowing the Wolfes makes this part of the story especially meaningful to me. Their support for the Center is not a one-time expression of generosity. It is part of a longstanding commitment to the Technion and Israel, and to the extraordinary potential they see in Israeli science and innovation.

That kind of sustained commitment matters. Andi and Larry did more than help make another research facility possible. Their philanthropy is helping create the conditions in which people who speak different professional languages can work on the same human problems.

They did more than support another research facility. Their philanthropy is helping create the conditions in which people who speak different professional languages can work on the same human problems.

We do not know which conversation between a physician and an engineer will eventually produce a breakthrough. We cannot know which question arising during a patient’s care will become a research project, or which experiment will ultimately return to another patient’s bedside as a treatment.

Philanthropy makes room for those possibilities. It brings disciplines together. It gives researchers the freedom to ask difficult questions. And sometimes, its greatest contribution is building the bridge between people who otherwise might never work together.

Andi and Larry’s relationship with American Technion Society and the Technion also illustrates something I have come to value deeply about philanthropy: the greatest impact often grows from relationships sustained over time. It comes from believing in an institution, understanding what it can accomplish, and being willing to help it take the next ambitious step.

That is why supporting Israeli science and working toward global human progress are not separate ambitions. They are increasingly part of the same story.

A discovery can begin with a patient at Rambam in Haifa. The solution might emerge through collaboration with an engineer at the Technion. But if that solution works, there is no reason its journey needs to end in Haifa, or even in Israel. It can travel.

What begins as one patient’s problem can ultimately become another patient’s possibility.

Back to the Bedside

In my first post, I wrote about the need to move “beyond familiarity and toward relevance,” showing how Israeli innovation is not only a source of pride but a force for global good.

The Andrea and Lawrence Wolfe Center for Translational Medicine and Engineering embodies that idea. So, in a very real sense, does the Wolfes’ enduring support for the institutions and people working to make that promise real.

Its success will not ultimately be measured only by the number of research projects undertaken, papers published, or patents produced.

It will be measured by whether questions become answers. Whether ideas become tools. Whether discoveries become treatments. And whether those treatments reach people who need them.

Prof. Gepstein described the agreement establishing the Center as “not the finish line, but the starting point.”

For philanthropy, I think that is exactly right.

A gift is rarely the beginning or the end of a relationship. At its best, it grows from years of shared commitment and trust, and it allows a much larger story to begin.

Somewhere at the end of that story is a patient. Perhaps in Israel. Perhaps thousands of miles away. That patient may never know the scientist who made the discovery, the engineer who designed the technology, or the donors whose generosity helped bring them together.

But the connection is real. That is Israeli innovation translated into human possibility.

And that is philanthropy at its most meaningful.

About the Author
Jenny Goldstein is Chief Development Officer of the American Technion Society. She has spent her two-decade career working at numerous Jewish and international NGOs, including Digital Divide Data, New York University, and American Jewish World Service. Most recently, Goldstein joined ATS in July 2025 following eight years at Americares, a global, health-focused disaster relief and development organization. She holds master’s degrees in public administration and Jewish studies from New York University, where she was a Wexner Graduate Fellow.
Sign in or Register
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Register
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.